COMMUNIQUÉS West-GlobeNewswire

Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
13/11/2026
JADE101 Phase 3 registrational trial in IgA nephropathy (EVERGREEN) expected to initiate in the fourth quarter of 2026 JADE101 Phase 2 clinical trial in IgA nephropathy (JUNIPER) ongoing; interim data expected in the [...]
Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update
13/11/2026
HOUSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule [...]
BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting
13/11/2026
— Two real-world studies demonstrate reductions in healthcare resource utilization in HAE patients who initiated or switched to ORLADEYO ® from another prophylactic therapy — RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2026 [...]
Contract Terms Shape How Quickly Outsourced Customer Support Can Scale Down After a Seasonal Spike
13/11/2026
The seat floor is the number of agents a company pays for every month, and it should equal the headcount it runs outside launches and holiday peaks. The notice period decides how early a company has to request a seat [...]
Joint replacement in Charleston: a credentials checklist for choosing an orthopedic surgeon
13/11/2026
Novant Health Orthopedics & Sports Medicine Institute outlines the credentials Charleston-area patients can check before a first visit and the questions to bring to a knee or hip replacement consultation Mount [...]
Milestone Pharmaceuticals Reports Third Quarter 2026 Financial Results and Announces Cost-Efficiency Measures Designed to Extend Cash Runway Through AFib-RVR Phase 3 Data
13/11/2026
Launch of CARDAMYST ® (etripamil) nasal spray marked by steady prescription growth, new prescriber expansion and improving commercial coverage Company is reducing operating expenses by approximately 30% while [...]
Milestone Scientific Reports Financial Results for Third Quarter 2026
13/11/2026
Medical Segment Revenue Grows 136% Year-Over-Year Expands CompuFlo® Physician Partnerships and Advances Medical Commercialization Online Demonstrations More Than Double Reflecting Increased Customer Engagement Reaffirms [...]
GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer
13/11/2026
Dr. Popova will lead the clinical development of GH001 as the company advances toward pivotal programs in TRD and PPD Brings more than 20 years of global pharmaceutical R&D experience at Johnson & Johnson across [...]
GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update
13/11/2026
Novel GH001 Aerosol Delivery System (ADS) device: final results of the GH001-HV-106 trial support going from 3 → 1 doses per treatment visit TRD pivotal program — positive initial feedback from FDA, End-of-Phase 2 [...]
Surrozen Announces Pricing of $60 Million Underwritten Offering of Common Stock
13/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling [...]
PDS Biotech Reports Third Quarter 2026 Financial Results
13/11/2026
PRINCETON, N.J., Nov. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company focused on transforming how the immune system [...]
IRulya Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
13/11/2026
Name changed from Quince Therapeutics, Inc. to IRulya Therapeutics Inc.; common stock began trading on the Nasdaq Capital Market under the ticker “IRLA” on October 12, 2026 Phase 2 data in bronchiolitis obliterans [...]
Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
13/11/2026
FDA lifted clinical hold on ARD-101 for the treatment of hyperphagia in Prader-Willi Syndrome (PWS) Meeting with the FDA scheduled for the first quarter of 2027 to discuss the Company’s proposed clinical development [...]
Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
13/11/2026
Total net revenue increased approximately 9% to $19.2 million for the third quarter of 2026 compared to the third quarter of 2025 Fortress repaid its credit facility in full in September 2026 A subsidiary of Fortress [...]
Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational Update
13/11/2026
Positive interim clinical results from the ongoing BB-301 Phase 1b/2a study for dysphagic patients with Oculopharyngeal Muscular Dystrophy (OPMD), presented as a late-breaking poster at the European Society of Gene and [...]
Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
13/11/2026
Last patient, last visit of the 6-month treatment period in the Phase 3 DUET-AD study is scheduled for December 31, 2026, with database lock on February 8, 2027, and data readout in March 2027 Parkinson’s disease open- [...]
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
13/11/2026
CONSHOHOCKEN, Pa., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: The fireside [...]
Biofrontera Inc. Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue Growth
13/11/2026
WOBURN, Mass., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic [...]
Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance
13/11/2026
- Ended third quarter with $24.1 million in cash and restricted cash - Expects positive fourth quarter earnings between $0.01 and $0.04 per share TARPON SPRINGS, Fla., November 13, 2026 – Allarity Therapeutics, Inc. (“ [...]

Pages